Heart-Assist Devices

• 

  Subject Areas on Research

  • 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. 
  • A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. 
  • A Machine Without an Owner's Manual. 
  • A Multicenter Trial of a Shared Decision Support Intervention for Patients and Their Caregivers Offered Destination Therapy for Advanced Heart Failure: DECIDE-LVAD: Rationale, Design, and Pilot Data. 
  • A contemporary review of mechanical circulatory support. 
  • A crisis of the heart: an acute reversible cardiomyopathy bridged to recovery in a patient with Addison's disease. 
  • A decade of short-term outcomes in post cardiac surgery ventricular assist device implantation: data from the Society of Thoracic Surgeons' National Cardiac Database. 
  • A global ranking approach to end points in trials of mechanical circulatory support devices. 
  • A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. 
  • A team-based approach to patients in cardiogenic shock. 
  • Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). 
  • Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. 
  • Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device. 
  • Advanced heart failure treated with continuous-flow left ventricular assist device. 
  • Advances in the surgical treatment of heart failure. 
  • After-hour ventricular assist device coverage: what level of expertise is required? 
  • Algorithm for the diagnosis and management of suspected pump thrombus. 
  • Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. 
  • Antithrombotic Strategies and Device Thrombosis. 
  • Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. 
  • Assessing Consequences of Intraaortic Balloon Counterpulsation Versus Left Ventricular Assist Devices at the Time of Heart Transplantation. 
  • Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support. 
  • Associations of Preimplant Red Blood Cell Distribution Width with Clinical Outcomes Among Individuals with Left Ventricular Assist Devices. 
  • BVS5000 support after cardiac transplantation. 
  • Balancing Bleeding and Clotting: The Known Unknowns of Mechanically Assisted Circulation. 
  • Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. 
  • Biventricular Support With Intracorporeal, Continuous Flow, Centrifugal Ventricular Assist Devices. 
  • Bleeding and thrombosis associated with ventricular assist device therapy. 
  • Bleeding complications and blood product utilization with left ventricular assist device implantation. 
  • Bridge to long-term mechanical circulatory support with a left ventricular assist device: novel use of transcatheter aortic valve replacement. 
  • Bridge to transplant with extracorporeal membrane oxygenation followed by HeartWare ventricular assist device in a child. 
  • Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. 
  • Cangrelor use prior to left ventricular assist device surgery: a case series. 
  • Capnocytophagia canimorsus sepsis in an asplenic heart transplant candidate with a left ventricular assist system. 
  • Cardiac Index Declines During Long-Term Left Ventricular Device Support. 
  • Cardiac implantable electronic device removal in patients with left ventricular assist device associated infections. 
  • Cerebral blood flow autoregulation is preserved after continuous-flow left ventricular assist device implantation. 
  • Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. 
  • Clinical Characteristics and Outcomes of Patients With Myocardial Infarction and Cardiogenic Shock Undergoing Coronary Artery Bypass Surgery: Data From The Society of Thoracic Surgeons National Database. 
  • Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Invited commentary. 
  • Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation. 
  • Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. 
  • Clinical outcome of mechanical circulatory support for refractory cardiogenic shock in the current era. 
  • Clinical outcomes after implantation of a centrifugal flow left ventricular assist device and concurrent cardiac valve procedures. 
  • Clinical pharmacology considerations for children supported with ventricular assist devices. 
  • Combined Therapy of Ventricular Assist Device and Membrane Oxygenator for Profound Acute Cardiopulmonary Failure. 
  • Comparative analysis of von Willebrand factor profiles in pulsatile and continuous left ventricular assist device recipients. 
  • Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. 
  • Computational fluid dynamics analysis to determine shear stresses and rates in a centrifugal left ventricular assist device. 
  • Concomitant Thoracic Aortobifemoral Bypass With Left Ventricular Assist Device Implantation. 
  • Concomitant tricuspid valve surgery during implantation of continuous-flow left ventricular assist devices: a Society of Thoracic Surgeons database analysis. 
  • Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. 
  • Cost of ventricular assist devices: can we afford the progress? 
  • Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. 
  • Development of a Pediatric Cardiac Mechanical Support Program. 
  • Device therapy in the management of congestive heart failure. 
  • Differential gene expression and genomic patient stratification following left ventricular assist device support. 
  • Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure. 
  • Disparities in access to left ventricular assist device therapy. 
  • Does a pre-left ventricular assist device screening score predict long-term transplantation success? A 2-center analysis. 
  • Does a pre-left ventricular assist device screening score predict long-term transplantation success? A 2-center analysis. 
  • Driveline Infection Risk with Utilization of a Temporary External Anchoring Suture After Implantation of a Left Ventricular Assist Device. 
  • Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device. 
  • Durable mechanical circulatory support devices. 
  • Dysphagia in the setting of left ventricular assist device hemolysis. 
  • ECMO and the Intraaortic Balloon Pump: In Search of the Ideal Mechanical Circulatory Support Device. 
  • Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. 
  • Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. 
  • Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. 
  • Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock. 
  • Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. 
  • Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. 
  • Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. 
  • Efficacy and durability of central oversewing for treatment of aortic insufficiency in patients with continuous-flow left ventricular assist devices. 
  • Endovascular stent grafting of a left ventricular assist device outflow graft pseudoaneurysm. 
  • Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. 
  • Evaluation of risk indices in continuous-flow left ventricular assist device patients. 
  • Exercise blood pressure response during assisted circulatory support: comparison of the total artificial [corrected] heart with a left ventricular assist device during rehabilitation. 
  • Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. 
  • First successful bridge to cardiac transplantation using direct mechanical ventricular actuation. 
  • Functional status in left ventricular assist device-supported patients: a literature review. 
  • Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. 
  • Glenn shunt facilitated weaning of right ventricular mechanical support. 
  • Heart failure medications prescribed at discharge for patients with left ventricular assist devices. 
  • HeartMate XVE malfunction caused by fluid aspiration into the vent port. 
  • HeartMate® II continuous-flow left ventricular assist system. 
  • Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. 
  • Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients. 
  • High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry. 
  • Highlights of the 2010 scientific sessions of the Heart Failure Society of America, San Diego, California, September 12-15, 2010. 
  • INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. 
  • Ideal methodology to assess systemic blood pressure in patients with continuous-flow left ventricular assist devices. 
  • Identification of Severe Mitral Stenosis Using Real-Time Three-Dimensional Transesophageal Echocardiography During an Left Ventricular Assist Device Insertion. 
  • Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. 
  • Impact of left ventricular assist device bridging on posttransplant outcomes. 
  • Impact of tricuspid valve regurgitation in patients treated with implantable left ventricular assist devices. 
  • Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices: On Trial and in Need of a Trial. 
  • Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. 
  • Important role of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock. 
  • Improved early survival with a nonsternotomy approach for continuous-flow left ventricular assist device replacement. 
  • Incidence and Impact of On-Cardiopulmonary Bypass Vasoplegia During Heart Transplantation. 
  • Incidence, risk, and consequences of atrial arrhythmias in patients with continuous-flow left ventricular assist devices. 
  • Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. 
  • Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure. 
  • Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. 
  • Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial. 
  • Initial Experience of Left Ventricular Assist Device Support for Adult Patients with Transposition of the Great Vessels. 
  • Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. 
  • Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. 
  • Intra-aortic balloon pump trials: questions, answers, and unresolved issues. 
  • Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. 
  • Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. 
  • Invited commentary. 
  • Is Four Stage Management the Future of Univentricular Hearts? Destination Therapy in the Young. 
  • Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. 
  • Left ventricular assist device destination therapy versus extended criteria cardiac transplant. 
  • Left ventricular assist device effects on metabolic substrates in the failing heart. 
  • Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. 
  • Left ventricular assist devices as destination therapy for end-stage heart failure. 
  • Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. 
  • Load-independent analysis of a pulsatile right ventricular assist device. 
  • Long-Term Survival in Patients Receiving a Continuous-Flow Left Ventricular Assist Device. 
  • Long-term follow-up of continuous flow left ventricular assist devices: complications and predisposing risk factors. 
  • Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. 
  • Long-term survival using intra-aortic balloon pump and percutaneous right ventricular assist device for biventricular mechanical support of cardiogenic shock. 
  • Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data. 
  • Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. 
  • Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. 
  • Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. 
  • Malpositioned left ventricular assist device cannula: diagnosis and management with transesophageal echocardiography guidance. 
  • Management of cardiogenic shock. 
  • Management of epistaxis in patients with ventricular assist device: a retrospective review. 
  • Management of pediatric tachyarrhythmias on mechanical support. 
  • Managing VAD Complications: Our Growth Industry. 
  • Marginal Donor Use in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation. 
  • Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. 
  • Mechanical unloading promotes myocardial energy recovery in human heart failure. 
  • Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congential heart disease. 
  • Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. 
  • Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. 
  • Migration of Intraaortic Balloon Pump Placed Via the Axillary Artery. 
  • My approach to evaluation of patients prior to high-risk PCI with left ventricular support devices. 
  • Myocardial scar in sarcoidosis by 12-lead ECG and pathology. 
  • Myocardial tolerance to mechanical actuation is affected by biomaterial characteristics. 
  • Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation. 
  • Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. 
  • Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support. 
  • Nonpharmacologic therapy in heart failure: an overview. 
  • Novel approaches to clinical trials: device-related infections. 
  • One-and-done: Do left ventricular assist device patients on the transplant list really need frequent right heart catheterization assessments for pulmonary hypertension? 
  • Optimism, Pessimism, and Pragmatism: Musings on the Cost of Medical Innovation. 
  • Orthostatic Hypotension in Patients With Left Ventricular Assist Devices: Acquired Autonomic Dysfunction. 
  • Outcomes after implantable left ventricular assist device replacement procedures. 
  • Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure. 
  • Outcomes in Patients Bridged With Univentricular and Biventricular Devices in the Modern Era of Heart Transplantation. 
  • Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. 
  • Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. 
  • PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. 
  • Paediatric cardiomyopathy and anaesthesia. 
  • Part II: Sealing holes in the safety net. 
  • Patient selection for left ventricular assist devices. 
  • Patient selection for mechanical circulatory support. 
  • Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management). 
  • Percutaneous Mechanical Circulatory Support Devices in Cardiogenic Shock. 
  • Percutaneous transcatheter aortic valve closure successfully treats left ventricular assist device-associated aortic insufficiency and improves cardiac hemodynamics. 
  • Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention--From the PROTECT II randomized trial. 
  • Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. 
  • Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. 
  • Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. 
  • Point-of-Care Rapid-Seeding Ventricular Assist Device with Blood-Derived Endothelial Cells to Create a Living Antithrombotic Coating. 
  • Positive Impact of Continuous-Flow Left Ventricular Assist Device Implantation on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Advanced Chronic Systolic Heart Failure. 
  • Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. 
  • Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. 
  • Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy. 
  • Preparedness planning before mechanical circulatory support: a "how-to" guide for palliative medicine clinicians. 
  • Presentation and management of left ventricular assist device inflow cannula malposition. 
  • Prognostic Impact of Pulmonary Artery Pulsatility Index (PAPi) in Patients With Advanced Heart Failure: Insights From the ESCAPE Trial. 
  • Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. 
  • Prognostic value of left ventricular apical tissue removed for HeartMate II left ventricular assist device placement. 
  • Prolonged total circulatory support using direct mechanical ventricular actuation. 
  • Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. 
  • Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial. 
  • Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry. 
  • Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation. 
  • Ramp Study Hemodynamics, Functional Capacity, and Outcome in Heart Failure Patients with Continuous-Flow Left Ventricular Assist Devices. 
  • Recurrence of cardiac sarcoidosis in a heart transplant recipient. 
  • Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction. 
  • Relation between pressure and volume unloading during ramp testing in patients supported with a continuous-flow left ventricular assist device. 
  • Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. 
  • Replacement of continuous-flow left ventricular assist device via left subcostal incision. 
  • Reply: Is Pump the Answer to Heart Failure With Preserved Ejection Fraction? 
  • Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). 
  • Rethinking papillary muscle resection for refractory ventricular tachycardia in the LVAD era. A case report. 
  • Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. 
  • Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. 
  • Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. 
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study. 
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. 
  • Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: design and rationale of the ROADMAP clinical trial. 
  • Risk factors for stroke on left ventricular assist devices. 
  • Risk of anaphylaxis from aprotinin re-exposure during LVAD removal and heart transplantation. 
  • Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. 
  • Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failure. 
  • Sharing the care of mechanical circulatory support: collaborative efforts of patients/caregivers, shared-care sites, and left ventricular assist device implanting centers. 
  • Successful organ donation after long-term circulatory support with nonpulsatile mechanical support. 
  • Surgical Technique for Replacement of Centrifugal Left Ventricular Assist Device Through a Left Thoracotomy. 
  • Surgical correction of aortic valve insufficiency after left ventricular assist device implantation. 
  • Surgical treatments for advanced heart failure. 
  • Survival After Orthotopic Heart Transplantation in Patients Undergoing Bridge to Transplantation With the HeartWare HVAD Versus the Heartmate II. 
  • Temporal changes in hospital costs for left ventricular assist device implantation. 
  • Temporary extracorporeal left ventricular assist device support for implantable left ventricular assist device replacement cases. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Diagnostic Yield of Repeated Endoscopic Evaluation in Patients with Gastrointestinal Bleeding and Left Ventricular Assist Devices. 
  • The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies. 
  • The Risk of Stroke on Left Ventricular Assist Device Support: Steady Gains or Stalled Progress? 
  • The biocompatibility of titanium cardiovascular devices seeded with autologous blood-derived endothelial progenitor cells: EPC-seeded antithrombotic Ti implants. 
  • The bispectral index in the diagnosis of perioperative stroke: a case report and discussion. 
  • The changing landscape of advanced heart failure therapeutics. 
  • The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. 
  • The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device. 
  • The spectrum of complications following left ventricular assist device placement. 
  • The year in cardiovascular surgery. 
  • Thoratec VAD system as a bridge to heart transplantation. 
  • Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. 
  • Thrombus around the redesigned HeartWare HVAD inflow cannula: A pathologic case series. 
  • Thrombus on the inflow cannula of the HeartWare HVAD: an update. 
  • Transcatheter aortic valve replacement performed via left ventricular assist device inflow cannula. 
  • Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. 
  • Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States. 
  • Trends in the use and outcomes of ventricular assist devices among medicare beneficiaries, 2006 through 2011. 
  • Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. 
  • Unexpected abrupt increase in left ventricular assist device thrombosis. 
  • Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. 
  • Use of HeartWare Ventricular Assist System for systemic ventricular support of a pediatric patient after Mustard procedure. 
  • Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart. 
  • Use of a continuous-flow device in patients awaiting heart transplantation. 
  • Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. 
  • Utility of concomitant tricuspid valve procedures for patients undergoing implantation of a continuous-flow left ventricular device. 
  • Valvular heart disease in patients supported with left ventricular assist devices. 
  • Ventricular assist devices and increased blood product utilization for cardiac transplantation. 
  • When VAD Things Happen to Good People. 
  • When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. 
  • Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. 
  • Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. 
  • Worldwide Experience of a Durable Centrifugal Flow Pump in Pediatric Patients. 
  • iPhone in the Management of the Berlin Heart EXCOR Ventricular Assist Device. 
  • von Willebrand Factor Abnormalities and Heyde Syndrome in Dysfunctional Heart Valve Prostheses. 
• 

  Keywords of People

  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic